UCSF breast cancer expert collaborates with Dalai Lama's doctor in Tibetan medicine study: Women needed to participate in trial

October 07, 1999

Faced with advanced breast cancer, hundreds of women from around the world have sought treatment from Yeshi Dhonden, one of the foremost living authorities on Tibetan medicine who was the Dalai Lama's personal physician for two decades.

Now, in an unprecedented clinical trial, Dhonden and breast cancer experts at the University of California, San Francisco are putting traditional Tibetan medicine to the test as the sole therapy for advanced breast cancer.

"This will be a preliminary study that will look for changes in the size of women's tumors," said Debu Tripathy, MD, director of clinical research at the UC San Francisco Carol Franc Buck Breast Care Center. "The investigational therapy will be individualized to a certain extent, with Dr. Dhonden choosing one of seven Formula for each woman based on his diagnosis and assessment."

UCSF is currently recruiting women for the Tibetan medicine trial, which is approved by the UCSF institutional review board and Food and Drug Administration (FDA). The state of California's Breast Cancer Research Program (BCRP) issued Tripathy a $50,000 grant to develop the study.

To date, no trials have been conducted on a sufficient scale and with the use of rigorous scientific methodologies to fully assess Tibetan medicine and diagnosis. Although Dhonden has treated an estimated 3,000 women with breast cancer during the past 20 years, the responses and clinical benefits are unknown because formal record keeping is not standard in Tibetan medicine.

Dhonden, who is based in Dharamsala, India, visits San Francisco once every four to six months to chart the progress of the women in the one-year trial. Study participants are prohibited from receiving any other treatments while enrolled in the trial, including both conventional and unconventional therapies. All patients will be regularly monitored with standard Western techniques including physical examinations, tomography scans and blood and liver function tests.

Women in the study are first examined by Dhonden who gives them a diagnosis and then prescribes an herbal therapy that is taken two to six times daily for one-year. Diagnosis Tibetan style is based on methods such as pulse readings, examination of a woman's tongue and of the color, odor and appearance of her urine.

These finely tuned techniques may detect subtle underlying differences between two breast cancer patients that conventional Western diagnosis often overlooks, Tripathy said. Further, he believes that Tibetan treatment, which provides individual therapies for each woman, may have a greater insight into treating cancer than the standard "one size fits all" Western approach.

Tibetan Buddhist medicine is based on a tradition that understands the body in terms of three "humors:" wind, bile, and phlegm-the imbalances which fundamentally derive from the three mental afflictions of attachment, hatred and delusion. In the Tibetan medical model of treatment for breast cancer, the prescribed therapy consists of herbal compounds designed to treat a woman's individual "humors" that are out of balance. Tibetan phytotherapy (herbal therapy) works by means of a synergistic action of the combination of individual herbs and other natural substances in a formula.

Patients who are eligible to participate in the trial must have a confirmed diagnosis of stage IV advanced breast cancer; have minimal tissue and organ damage; be relatively healthy with no major symptoms; and have not used any experimental agents, herbal medication or anti-tumor therapies for at least three weeks prior to enrollment.

For more information on the study, please call the Complementary and Alternative Medicine program at 415-353-7682.
-end-


University of California - San Francisco

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.